183 related articles for article (PubMed ID: 15094397)
21. [Therapeutic strategies for the polyglutamine diseases].
Nagai Y; Popiel HA; Fujikake N; Toda T
Brain Nerve; 2007 Apr; 59(4):393-404. PubMed ID: 17447526
[TBL] [Abstract][Full Text] [Related]
22. p97 Homologs from Caenorhabditis elegans, CDC-48.1 and CDC-48.2, suppress the aggregate formation of huntingtin exon1 containing expanded polyQ repeat.
Nishikori S; Yamanaka K; Sakurai T; Esaki M; Ogura T
Genes Cells; 2008 Aug; 13(8):827-38. PubMed ID: 18782221
[TBL] [Abstract][Full Text] [Related]
23. PolyQ fibrillation in the cell nucleus: who's bad?
von Mikecz A
Trends Cell Biol; 2009 Dec; 19(12):685-91. PubMed ID: 19796946
[TBL] [Abstract][Full Text] [Related]
24. Monitoring polyglutamine toxicity in yeast.
Duennwald ML
Methods; 2011 Mar; 53(3):232-7. PubMed ID: 21144902
[TBL] [Abstract][Full Text] [Related]
25. Intracellular aggregate formation of dentatorubral-pallidoluysian atrophy (DRPLA) protein with the extended polyglutamine.
Miyashita T; Nagao K; Ohmi K; Yanagisawa H; Okamura-Oho Y; Yamada M
Biochem Biophys Res Commun; 1998 Aug; 249(1):96-102. PubMed ID: 9705838
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of polyglutamine aggregate cytotoxicity by a structure-based elongation inhibitor.
Thakur AK; Yang W; Wetzel R
FASEB J; 2004 May; 18(7):923-5. PubMed ID: 15001566
[TBL] [Abstract][Full Text] [Related]
27. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity.
Chen S; Berthelier V; Yang W; Wetzel R
J Mol Biol; 2001 Aug; 311(1):173-82. PubMed ID: 11469866
[TBL] [Abstract][Full Text] [Related]
28. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.
Nagai Y; Fujikake N; Ohno K; Higashiyama H; Popiel HA; Rahadian J; Yamaguchi M; Strittmatter WJ; Burke JR; Toda T
Hum Mol Genet; 2003 Jun; 12(11):1253-9. PubMed ID: 12761040
[TBL] [Abstract][Full Text] [Related]
29. Phage display screening for peptides that inhibit polyglutamine aggregation.
Kenan DJ; Strittmatter WJ; Burke JR
Methods Enzymol; 2006; 413():253-73. PubMed ID: 17046401
[TBL] [Abstract][Full Text] [Related]
30. An Expanded Polyproline Domain Maintains Mutant Huntingtin Soluble
Pigazzini ML; Lawrenz M; Margineanu A; Kaminski Schierle GS; Kirstein J
Front Mol Neurosci; 2021; 14():721749. PubMed ID: 34720872
[TBL] [Abstract][Full Text] [Related]
31. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.
Popiel HA; Nagai Y; Fujikake N; Toda T
Neurosci Lett; 2009 Jan; 449(2):87-92. PubMed ID: 18603372
[TBL] [Abstract][Full Text] [Related]
32. Proteasome degrades soluble expanded polyglutamine completely and efficiently.
Michalik A; Van Broeckhoven C
Neurobiol Dis; 2004 Jun; 16(1):202-11. PubMed ID: 15207277
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the two p97/VCP/Cdc48p proteins of Caenorhabditis elegans and their suppression of polyglutamine-induced protein aggregation.
Yamanaka K; Okubo Y; Suzaki T; Ogura T
J Struct Biol; 2004; 146(1-2):242-50. PubMed ID: 15037255
[TBL] [Abstract][Full Text] [Related]
34. Neuronal toxicity of expanded polyglutamine depends on intracellular distribution in addition to the expression level.
Satoh M; Shimada A; Kawamura N; Chiba Y; Yoshikawa K; Ishii S; Furukawa A; Kumagai N; Hosokawa M
Neuropathology; 2008 Oct; 28(5):485-96. PubMed ID: 18384512
[TBL] [Abstract][Full Text] [Related]
35. The rate of polyQ-mediated aggregation is dramatically affected by the number and location of surrounding domains.
Robertson AL; Bate MA; Buckle AM; Bottomley SP
J Mol Biol; 2011 Nov; 413(4):879-87. PubMed ID: 21945530
[TBL] [Abstract][Full Text] [Related]
36. Essential fatty acids in Huntington's disease.
Das UN; Vaddadi KS
Nutrition; 2004 Oct; 20(10):942-7. PubMed ID: 15474886
[TBL] [Abstract][Full Text] [Related]
37. Huntingtin aggregation and toxicity in Huntington's disease.
Bates G
Lancet; 2003 May; 361(9369):1642-4. PubMed ID: 12747895
[TBL] [Abstract][Full Text] [Related]
38. Evidence for polyproline II helical structure in short polyglutamine tracts.
Chellgren BW; Miller AF; Creamer TP
J Mol Biol; 2006 Aug; 361(2):362-71. PubMed ID: 16854433
[TBL] [Abstract][Full Text] [Related]
39. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.
Bauer PO; Nukina N
J Neurochem; 2009 Sep; 110(6):1737-65. PubMed ID: 19650870
[TBL] [Abstract][Full Text] [Related]
40. Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.
Takeuchi T; Popiel HA; Futaki S; Wada K; Nagai Y
Curr Med Chem; 2014; 21(23):2575-82. PubMed ID: 24533807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
